Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. (APLS) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
apls · stock forecast · 25 analysts (3M) · FMP · updated May 20, 2026
Analyst Rating & Consensus
Based on 25 Wall Street analysts in the past 3 months
Buy
25 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$48.00
Consensus
$33.40
-18.6% upside
Low
$19.00
Median: $35 · Last Close: $41.03
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$33.40
-18.6% upside
High Target
$48
17.0%
Low Target
$19
-53.7%
Current Price
$41.03
as of today
Based on analyst price targets, the APLS stock price prediction for the next 12 months ranges from $19 to $48. The consensus APLS price forecast of $33.40 implies -18.6% upside from the current price of $41.03.
Short-Term Price Prediction
RangingAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $41.02 | ↓ 0.02% |
1-day model range: $41.01–$41.03. Peak: $41.03 (-0.02%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · APLS · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-09-24 | Wells Fargo | Maintains | Equal Weight→Equal Weight |
| 2024-09-23 | Baird | Maintains | Outperform→Outperform |
| 2024-09-20 | Needham | Maintains | Buy→Buy |
| 2024-09-20 | Mizuho | Maintains | Neutral→Neutral |
| 2024-09-13 | JP Morgan | Maintains | Overweight→Overweight |
| 2024-08-13 | JP Morgan | Maintains | Overweight→Overweight |
| 2024-08-09 | Needham | Maintains | Buy→Buy |
| 2024-08-09 | Wedbush | Maintains | Neutral→Neutral |
| 2024-08-09 | Goldman Sachs | Maintains | Buy→Buy |
| 2024-08-09 | UBS | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Apellis Pharmaceuticals, Inc. (APLS) stock. Of the recent 187 rating actions, 9 were upgrades and 14 were downgrades. 25 analysts currently cover APLS.
Analyst Recommendation Trends
APLS analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 3 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$871M
↓ 31.0% YoY
Revenue Next Year
$1.0B
↑ 17.8% YoY
EPS This Year
$-1.03
EPS Next Year
$-0.07
↓ 93.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast APLS EPS of $-1.03 for the current fiscal year, based on estimates from 8 analysts. The APLS revenue forecast is $871M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The APLS stock forecast is supported by two independent data sources: analyst consensus ratings from 25 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus APLS price target is $33.40 (-18.6% upside), with an analyst consensus of Buy.
The APLS short-term stock prediction for tomorrow is $41.02 (-0.02%).
Apellis Pharmaceuticals, Inc. trades on NASDAQ under the ticker APLS. The APLS stock outlook for 2027 is broadly positive, supported by a Buy consensus among 72% of covering analysts.
Frequently asked questions
APLS forecast · 8 questionsAccording to 25 Wall Street analysts, the average 12-month APLS price target is $33.40, with a high forecast of $48.00 and a low of $19.00. The median price target is shown in the chart above when available. This implies -18.6% potential upside from the current price of $41.03.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.